Aroa Biosurgery (ASX:ARX) reported Thursday that its fiscal year 2025 loss narrowed to NZ$0.0111 per diluted share from a loss of NZ$0.0309 per diluted share a year earlier.
Analysts polled by Visible Alpha were expecting a loss per diluted share of NZ$0.6.
Revenue for the year ended March 31 was NZ$84.7 million, up 23% from NZ$69.1 million in the same period last year. Analysts surveyed by Visible Alpha expected NZ$81.1 million.
For fiscal year 2026, the company expects revenue in the range of N$92 million to NZ$100 million. Analysts polled by Visible Alpha expect earnings of NZ$1.1 per diluted share on revenue of NZ$102.2 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.